In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Interventional Technologies Inc.

Division of Boston Scientific Corp.

Latest From Interventional Technologies Inc.

Pathway Medical: Pursuing the Hawk

Two years ago, Pathway Medical was nearly out of business. Now it's back, pursuing one of the hottest opportunities in cardiovascular medicine: atherectomy to treat peripheral artery disease.

Medical Device

In Device M&A, Happy Days are Here Again

After dropping markedly for two consecutive years, both the number of acquisitions in medical devices and the total dollar volume of those deals jumped significantly in 2003, reaching 71 and $9.17 billion, respectively. And if the dollar volumes and number of deals in 2003 weren't good news enough, an analysis of some of the trends behind the deal-making should give device executives even more cause to be happy. Thus, while a significant number of the total deals do fall within only two clinical categories, cardiovascular and orthopedics, the larger picture shows an M&A climate that is quite diversified. Similarly, the perception that deal-making is concentrated in the hands of a small group of large companies isn't borne out by the data. That said, new technology trends, most notably the convergence of drugs and devices, and new deal structures suggest, at least anecdotally, that device M&A may be changing.

Medical Device

Two Cheers for Evidence-Based Medicine

In recent years, evidence-based medicine has had an important influence on cardiovascular devices, but it's easy to overlook the staying power of subjective judgment. At a session on "What's the Science on Niche Devices?" held during this year's American Heart Association meeting, the cardiologist-audience clearly didn't seem deterred from using certain devices such as DCA and rotoblators, despite equivical or mediocre results in clinical trials.

Medical Device Innovation

Dealmaking on a Small Planet: Medical Device Transactions 2001

Dealmaking in the device industry is occasional and incremental when compared with the level of activity in pharmaceuticals, the result of that industry's maturing into a handful of dominant players, not all of which see acquisitions as strategically critical to their long-term success. The less-than-robust public market for small device companies is both symptom and cause of the device dealmaking lull. Because the markets they target are generally too small to sustain years of significant growth, few investors are willing to invest in them as stand-alone companies. And without long-term investor support, smaller firms have few options other than to sell out to large companies and little negotiating leverage when they do so.

Medical Device Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Boston Scientific Corp.
  • Senior Management
  • Herbert Radisch, VP, R&D
  • Contact Info
  • Interventional Technologies Inc.
    Phone: (619) 268-4488
    3574 Ruffin Road
    San Diego, CA 92123-